Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of BC-006 plus tirzepatide in adults with obesity
ISRCTN83576037Phase 2Active, not recruiting
- Sponsor
- BaseCure Therapeutics
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of muzastotug and tirzepatide in obesity (4 arms), sponsored by BaseCure Therapeutics. Primary endpoint: Not specified. Started Feb 2026; status: active, not recruiting.
02
Drugs
muzastotugtirzepatide
03
Conditions
obesity
Beyond the preview
Go deeper on ISRCTN83576037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83576037.